Trial Profile
A Single Center, Open Label Clinical Trial Investigating the Long-term Efficacy of rhLAMAN (Recombinant Human Alpha-mannosidase or Lamazym) Treatment in Subjects With Alpha-Mannosidosis Who Previously Participated in Lamazym Trials
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Velmanase alfa (Primary)
- Indications Alpha-Mannosidosis
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Zymenex A/S
- 14 Jul 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 11 Feb 2015 New trial record